• 1
    Whitaker D, Sterrett G, Shilkin K. Early diagnosis of malignant mesothelioma: the contribution of effusion and fine needle aspiration cytology and ancillary techniques. In: Peters GA, Peters BJ, eds. Sourcebook on Asbestos Diseases: Medical, Legal and Engineering Aspects. Vol 4. New York: Garland Law Publishing; 1989:71115.
  • 2
    Whitaker D, Sterrett G, Shilkin KB. Mesotheliomas. In: Gray W, ed. Diagnostic Cytopathology. New York: Churchill Livingstone; 1995:195224.
  • 3
    Whitaker D, Shilkin KB. Diagnosis of pleural malignant mesothelioma in life–a practical approach. J Pathol. 1984;143:147175.
  • 4
    Triol JH, Conston AS, Chandler SV. Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital. Acta Cytol. 1984;28:3745.
  • 5
    Butler EB, Berry AV. Diffuse mesotheliomas. Diagnostic criteria using exfoliative cytology. In: Bogovski P, Gilson JC, Timbrell V, Wagner JC, eds. Biological Effects of Asbestos. Lyon, France: International Agency for Research on Cancer; 1973:6873.
  • 6
    Ehya H. The cytologic diagnosis of mesothelioma. Semin Diagn Pathol. 1986;3:196203.
  • 7
    Klempman S. The exfoliative cytology of diffuse pleural mesothelioma. Cancer. 1962;15:691704.
  • 8
    Naylor B. The exfoliative cytology of diffuse malignant mesothelioma. J Pathol Bacteriol. 1963;86:293298.
  • 9
    Stevens MW, Leong AS-Y, Fazzalari NL, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma. A step-wide logistic regression analysis. Diagn Cytopathol. 1992;8:333341.
  • 10
    Delahaye M, de Jong AA, Versnel MA, Hoogsteden HC, Teeling P, van der Kwast TH. Cytopathology of malignant mesothelioma. Reappraisal of the diagnostic value of collagen cores. Cytopathology. 1990;1:137145.
  • 11
    Naylor B. Pleural, peritoneal and pericardial fluids. In: Bibbo M, ed. Comprehensive Cytopathology. Philadelphia: WB Saunders; 1991:590610.
  • 12
    Kho-Duffin J, Tao L-C, Cramer H, Catellier MJ, Irons D, Ng P. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol. 1999;20:5762.
  • 13
    Whitaker D. The cytology of malignant mesothelioma. Cytopathology. 2000;11:139151.
  • 14
    Leong ASY, Stevens MW, Mukherjee TM. Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical and ultrastructural correlation. Semin Diagn Pathol. 1992;9:141150.
  • 15
    Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38:874879.
  • 16
    Cakir E, Demirag F, Aydin M, Unsal E. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol. 2009;37:410.
  • 17
    Lee JS, Nam JH, Lee MC, Park CS, Juhng SW. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serous effusions. Acta Cytol. 1996;40:631636.
  • 18
    Van der Kwast TH, Versnel MA, Delahaye M, de Jong A, Zondervan PE, Hoogsteden H. Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study. Acta Cytol. 1988;32:169174.
  • 19
    Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology. 1997;31:140143.
  • 20
    Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:10371046.
  • 21
    Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998;22:12151221.
  • 22
    Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol. 1994;11:237245.
  • 23
    Tickman RJ, Cohen C, Varma VA, Fekete PS, DeRose PB. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry. Acta Cytol. 1990;34:491496.
  • 24
    Frisman DM, McCarthy WF, Schleiff P, Buckner SB, Nocito JD Jr, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol. 1993;6:179184.
  • 25
    Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer (Cancer Cytopathol). 2010;118:9096.
  • 26
    Hyun TS, Barnes M, Tabatabai ZL. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology. Acta Cytol. 2012;56:527532.
  • 27
    Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol. 2011;39:313317.
  • 28
    Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferation. Am J Surg Pathol. 2000;24:11831200.